{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:46:35Z","timestamp":1776253595253,"version":"3.50.1"},"reference-count":62,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Approximately 50% of the mortality in chronic dialysis patients is due to cardiovascular diseases (CVD). Cardiomyopathy, coronary artery disease, and arrhythmia are all common conditions and predispose to sudden death, which accounts for 60% of all cardiac deaths in this population. Despite advances in dialysis therapy, the mortality from CVD remains substantially unchanged, partly due to the lack of evidence\u2010based strategies for improving the outcome of cardiac diseases in this population. Activation of the sympathetic adrenergic system is well documented in chronic dialysis patients and is likely involved in the pathogenesis of myocardial hypertrophy, coronary artery disease, heart failure, and arrhythmia. Given the proven benefit of \u03b2\u2010blockers in patients with normal kidney function with similar cardiac comorbidities, \u03b2\u2010blockers would seem to be attractive agents to reduce cardiovascular morbidity and mortality in the patient population with advanced chronic kidney disease. However, the value of \u03b2\u2010blockade in patients on chronic dialysis remains unclear. This uncertainty surrounding the efficacy is compounded by the risk of side effects to these patients, such as hypotension, bradycardia, and hyperkalemia. In addition, numerous studies have suggested suboptimal usage of \u03b2\u2010blockers in the dialysis population; this is seen even in high risk patients, such as those with established coronary artery disease. In this review, we will focus on sympathetic nervous system activation in kidney disease and highlight the benefit and risks of \u03b2\u2010blockers usage in the chronic dialysis patient population.<\/jats:p>","DOI":"10.1111\/j.1525-139x.2007.00367.x","type":"journal-article","created":{"date-parts":[[2007,10,3]],"date-time":"2007-10-03T06:49:43Z","timestamp":1191394183000},"page":"43-48","source":"Crossref","is-referenced-by-count":35,"title":["<i>Review<\/i>: \u03b2\u2010Blockade in Chronic Dialysis Patients"],"prefix":"10.1111","volume":"21","author":[{"given":"Seth B.","family":"Furgeson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,10]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.9.1207"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12122753"},{"key":"e_1_2_8_4_2","volume-title":"USRDS 2006 Annual Data Report","author":"US Renal Data System","year":"2006"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh516"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.00806.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1681\/ASN.V361238","article-title":"Outcomes of cardiopulmonary resuscitation in dialysis patients","volume":"3","author":"Moss AH","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000013500"},{"key":"e_1_2_8_9_2","volume-title":"USRDS 2002 Annual Data Report","author":"US Renal Data System","year":"2002"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0894-0959.2004.17318.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1681\/ASN.V961018","article-title":"Myocyte\/capillary mismatch in the heart of uremic patients","volume":"9","author":"Amann K","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00391.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26381"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00676-3"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90629-2"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)90185-6"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.6.2852"},{"key":"e_1_2_8_18_2","first-page":"I5","article-title":"Effect of propranolol on ventricular arrhythmia. The beta\u2010blocker heart attack trial experience","volume":"67","author":"Lichstein E","year":"1983","journal-title":"Circulation"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.10.1295"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605233342101"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc1102.105261"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001835"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.5.2_Pt_2.I155"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.103"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000113320.57127.B9"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2001.28090"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212313272704"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.17.6.1057"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V12112427"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.6.641"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.13.5_Suppl.I57"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198303173081102"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/hc4301.098282"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)01254-6"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00900-1"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/14734220310011716"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-7-200104030-00008"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565060-00006"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13800-7"},{"key":"e_1_2_8_40_2","first-page":"57","article-title":"Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS\u20101","volume":"2","author":"ISIS\u20101 Collaborative Group","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90968-I"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003950070008"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.22.2465"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00636.x"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00241-9"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.5.484"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.5.558"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02360706"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00473.x"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.00359.x"},{"key":"e_1_2_8_51_2","first-page":"47","article-title":"Antihypertensive treatment with a vasodilating beta\u2010blocker, carvedilol, in chronic hemodialysis patients","volume":"43","author":"Deetjen A","year":"1995","journal-title":"Clin Nephrol"},{"key":"e_1_2_8_52_2","first-page":"198","article-title":"Effects of antihypertensive drugs on dialysis\u2010resistant hypertension, plasma renin and dopamine betahydroxylase activities, metabolic risk factors and calcium phosphate homeostasis: comparison of metoprolol, alphamethyldopa and clonidine in a cross\u2010over trial","volume":"12","author":"De Fremont JF","year":"1979","journal-title":"Clin Nephrol"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00548774"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1990.47"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1159\/000046255"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP57352"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1159\/000167176"},{"key":"e_1_2_8_58_2","first-page":"572","article-title":"Increase in serum potassium caused by beta\u20102 adrenergic blockade in terminal renal failure: absence of mediation by insulin or aldosterone","volume":"20","author":"Arrizalabalaga P","year":"1983","journal-title":"Proc Eur Dial Transplant Assoc"},{"key":"e_1_2_8_59_2","first-page":"584","article-title":"Effects of cardioselective and nonselective adrenergic blockade on serum potassium in patients with chronic renal failure undergoing haemodialysis","volume":"26","author":"Ozuer M","year":"1984","journal-title":"Kidney Int"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1159\/000058396"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.7.3.243"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0186"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.18.2227"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-139X.2007.00367.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-139X.2007.00367.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T01:08:51Z","timestamp":1697159331000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-139X.2007.00367.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1525-139X.2007.00367.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-139x.2007.00367.x","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}